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Venous thrombosis, including deep-vein thrombosis
and pulmonary embolism, is a common cause of morbidity
and mortality, particularly in older people.1 Venous throm-
bosis (VT) is multifactorial, and its exact pathogenesis has
not been fully elucidated. Most cases of venous thrombosis
arise due to prolonged immobilization, major surgery,
trauma, or cancer, but genetic or acquired hemostatic ab-
normalities, including elevated plasma homocysteine (Hcy)
levels, have also been implicated.2 Elevated concentrations
of total homocysteine have been associated with an
increased risk of arterial and venous thrombosis.3-5 A point
mutation, C to T substitution at the nucleotide 677, in the
coding sequence of the gene for methylenetetrahydrofolate
reductase (MTHFR) is the most common enzyme defect
associated with moderately-raised homocysteine concentra-
tions, particularly in the presence of a suboptimal folate in-
take.6 Genetic analyses studying the prevalence of the 677
C to T mutation in the MTHFR gene have recently shown
divergent results in patients with venous thrombotic disease
from different geographic regions. Several studies in
patients with venous thrombosis failed to demonstrate an
association between MTHFR C677T polymorphism and
increased risk of venous thrombotic disease,7,8,19-22 whereas
other studies have reported a positive association.9,17,18 In
view of this controversy, our study was conducted with the
purpose of evaluating the potential association of the
C677T mutation of the MTHFR gene with venous throm-
bosis in adult patients.
Materials and Methods
Patients and Controls
The present case control study included 200 patients with
VT and 100 healthy controls. Cases and controls were recruited
simultaneously from the same geographic area. Diagnosis of VT
was made by ultrasonography, radioisotope venography, and
magnetic resonance imaging angiography.22 Patients who had an
acquired disorder that predisposed them to VT were excluded
from the study. These acquired disorders included malignancy,
myeloproliferative disorder, nephrotic syndrome, liver disease,
antiphospholipid syndrome, or pregnancy. The inclusion criteria
for controls were: routine biochemical values within the normal
range, nonsmokers, and no history of metabolic, renal,
malignant, or vascular pathology. The exclusion criteria also in-
cluded history of thrombosis and supplementary intake of vita-
mins. Homocysteine assay was carried out by ELISA method
using Axis Homocysteine kit (Axis-Shield, Dundee, Scotland).
Genetic Analysis
Genomic DNA was extracted from the peripheral blood
leukocytes by a previously described method.10 The C677T mu-
tation in the MTHFR gene was analyzed by PCR-RFLP using
forward primer 5'-TGAAGGAGAAGGTGTCTGCGGGA-3'
and reverse primer 5'-AGGACGGTGCGGTGAGAGTG-3'.
PCR was carried out in a total volume of 40 µL containing 0.5
µmol/L of each primer, 200 µmol/L of all 4 dNTPs, 10 mmol/L
Tris-HCl (pH 8.9), 2.2 mmol/L MgCl2, 10% glycerol, 50
mmol/L KCl, 1.5 U of AmpliTaq DNA polymerase (Applied
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Abstract
Background: Venous thrombosis is a
multicausal disease involving acquired and
genetic factors. The prevalence of
methylenetetrahydrofolate reductase (MTHFR)
C677T genotypes and its association with
venous thrombosis is not established in the
Iranian population. In this study we investigated
a possible association between fasting
hyperhomocysteinemia and C677T mutation in
the MTHFR gene with venous thrombosis.
Materials and Methods: We studied 200
venous thrombotic patients and 100 healthy
controls, of similar age and sex. Mutation
analysis was carried out by PCR-RFLP, and the
homocysteine level was measured by EIA.
Results: No significant differences in the
frequency of C677T genotypes were observed
between patients and controls (P=0.2). The
frequency of the T allele was 21% and 27.2%
in controls and patients, respectively (odds
ratio, 1.27; 95% CI, 0.83–1.94, P=0.15).
Fasting homocysteine level was significantly
higher in patients than controls (P=0.001).
Conclusions: We concluded that
hyperhomocysteinemia, but not MTHFR C677T
mutation, is a significant risk factor for venous
thrombosis in the Iranian population, and
measuring the level of homocysteine is less
expensive and more useful than the genetic
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Biosystems, Foster City, CA), and 200 ng of template DNA.
The reaction conditions were as follows: initial denaturation at
94°C for 2 minutes and 35 subsequent cycles of denaturation 
at 94°C for 30 seconds, annealing at 62°C for 30 seconds, and
extension at 72°C for 30 seconds. PCR product (22 µL) was
digested with 0.5 µL (5 u) of Hinf I for 12 hours at 37°C. Di-
gestion of the 198 bp fragment of the 677CT genotype results
in 3 fragments of 198 bp, 175 bp, and 23 bp, whereas the 677
TT genotype results in 2 fragments of 175 bp and 23 bp. DNA
fragments were separated by electrophoresis on a 3% agarose gel
and visualized with ethidium bromide. Due to its small size, the
23 bp fragment was not seen on the gel.
Statistical Analysis
Allele frequencies were calculated by gene counting in pa-
tients and controls. The Hardy-Weinberg equilibrium was ana-
lyzed by the chi-square test for all the genotypes, and category
variables were analyzed with the chi-square test. Mean quantita-
tive variables between the groups were detected using Student’s 
t-test.
Logistic regression was used to assess the association of
MTHFR C677T mutation with VT, and odds ratio (OR) and
95% confidence interval (CI) were calculated after adjustment
for age and sex, and a P value <0.05 was considered significant.
Results
In total, 200 patients and 100 controls were included in
genetic analyses. Between the patients with VT and control
subjects, no significant differences were observed in mean age
and gender (Table 1). Mean plasma homocysteine levels were
significantly higher in the VT group (17.4 ± 7.1 µmol/L) than
in the control group (10.9 ± 4.1 µmol/L) (Table 1). 
The genotype and allele frequencies of the MTHFR gene
C677T mutation in VT patients and controls are shown in
Table 2. The genotype frequency did not differ significantly
between the 2 groups. The distributions of genotype in the 2
groups were in agreement with those predicted by Hardy-Wein-
berg equilibrium. The frequency of the T allele in the VT and
control groups after adjusting for age and sex were 27.2% and
21%, respectively (odds ratio=1.27, 95% CI, 0.832–1.940,
P=0.15).
The association between MTHFR genotypes and homocys-
teine concentration is significant in both patients (P=0.004) and
controls (P=0.03), as shown respectively in Figures 1A and 1B.
Discussion
Hyperhomocysteinemia is an independent risk factor for
cardiovascular disease that is influenced by factors such as nutri-
tional deficiencies, malignancies, medications, and mutations in
the MTHFR gene.11-13 C677T is the most well-described muta-
tion of this gene that affects homocysteine metabolism.14 The
defect causes a reduction in MTHFR activity and may lead to
hyperhomocysteinemia, a condition included among the disor-
ders of venous and arterial occlusive disease.15-16 Nevertheless,
the relationship between the TT genotype of the MTHFR gene
Table 1_Homocysteine Levels and Other Characteristics
in VT Patients and Control Group
VT Group Control Group P value
Number 200 100 –
Age 42.03 ± 13.49 38.17 ± 8.18 0.4
Gender (male/female) 95/105 45/55 0.85
Homocysteine (µmol/L) 17.4 ± 7.1 10.9 ± 4.1 0.001
Values are mean ± standard deviation. Chi-square test was used to compare gender
between the 2 groups and mean values of age and homocysteine were analyzed by
Student’s t-test. VT, venous thrombosis.
Table 2_MTHFR Genotypes and Allelic Frequencies 
of VT Patients and Controls
Genotype Allele
CC CT TT C T
Control (n=100) 62 (62.0) 34 (34.0) 4 (4.0) (79.0) (21.0)
VT (n=200) 109 (54.5) 73 (36.5) 18 (9.0) (72.8) (27.2)
P value 0.2 0.15
CC, wild type; CT, heterozygosity; TT, homozygosity; VT, venous thrombosis.
Numbers in parentheses represent percentages.
Figure 1_Effects of MTHFR genotypes on tHcy levels in patients (A) and controls (B). Analysis of covariance was used to compare homocystein
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and VT remains controversial. Some reports17-18 identified the
TT genotype as a genetic risk for VT; however, subsequent re-
ports19-22 did not confirm a positive relationship between the
TT genotype and VT.
In the present study, homozygous (TT) mutation of
MTHFR was not associated with VT, but had higher plasma
Hcy levels than normal (CC) or heterozygous (CT) genotypes.
This complies with the notion that both congenital and
acquired factors affect plasma Hcy levels,23-24 and thus homozy-
gous MTHFR mutation contributes indirectly to thrombosis 
via influencing plasma Hcy levels.25 Our study is consistent 
with many case-control studies19-21,26,27 showing no association
between MTHFR C677T mutation and VT. Our results also
are inconsistent with studies conducted in French,28 Italian,29
Chinese,30 and Spanish31 populations. The reasons for non-
replication of associated studies are numerous and many factors,
such as population heterogeneity, ethnic stratification, and sam-
ple size, may contribute to variable association results. Popula-
tion-specific linkage disequilibrium between markers and causal
variants, variation in study design, confounding sampling bias,
misclassification of phenotypes, and gene-gene and gene-envi-
ronment interactions are other factors that influence genetic 
association results.
The frequency of T allele in our study was 25%, which is
lower than the frequency reported in Italian32 (44%) and Turk-
ish33 (33.6%) populations and higher than Canadian Inuit34
(6%) and South African35 (10.3%) populations. Our result was
also comparable with frequency of T allele in Brazilian36 (24%)
and Taiwanese Chinese37 (24.4%) populations.
A large number of epidemiological studies9,11 have demon-
strated that mild to moderate hyperhomocysteinemia is a preva-
lent risk factor for cardiovascular disease and venous
thromboembolism with some exceptions.38-39 A meta-analysis
by den Heijer and colleagues40 demonstrated a significant odds
ratio of 2.5 (95% CI, 1.8 to 3.5) for VT in patients with fasting
hyperhomocysteinemia. In another meta-analysis41 including 27
studies relating homocysteine to atherosclerotic vascular disease,
the odds ratio was estimated to increase 1.6 for every 5 µmol/L
of elevated plasma homocysteine. In accordance with these re-
ports, our study implied a positive association between hyperho-
mocysteinemia and VT.
In conclusion, our results from an Iranian population pro-
vide evidence that plasma homocysteine level but not C677T
mutation of the MTHFR gene is a significant risk factor in VT
and measuring the level of homocysteine is cheaper and more
useful than the genetic test for the MTHFR mutation. LM
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